title: Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine.
abstract: A paradigm-shift in the management of non-small cell lung cancer (NSCLC) has resulted in many new therapies becoming available for patients with advanced disease. Stratification of treatment by histologic and molecular subtype is recommended to obtain the greatest clinical benefit for patients while minimizing adverse effects of treatment. However, these advances in diagnosis and treatment of NSCLC have come at a financial cost. This review highlights the economic impact of screening for molecular abnormalities and targeted treatment for advanced NSCLC. Major determinants of cost are drug acquisition and molecular testing. As technologies advance, molecular testing costs may reduce. However, we must collaborate with payers and manufacturers to ensure that high drug costs do not limit patient accessibility to potentially beneficial treatment.
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, Princess Margaret Cancer Centre, University of Toronto , Toronto, ON , Canada.
authors.forename: Donna M
authors.initials: DM
authors.lastname: Graham
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, Princess Margaret Cancer Centre, University of Toronto , Toronto, ON , Canada.
authors.forename: Natasha B
authors.initials: NB
authors.lastname: Leighl
keywords: economic impact; medical economics; metastatic NSCLC; personalized medicine; tissue testing